Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04310826 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04310826 · ClinicalTrials.gov record · last posted 2026-08-21

Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy

StatusActive, Not Recruiting
PhaseNot applicable
Started2019-04-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.

Protocol amendment history 2 changes detected by DataLookout

2026-08-22
Primary completion pushed: 2026-04-01 → 2028-04-01
2026-08-22
Completion pushed: 2026-04-01 → 2028-04-01
Trial Details
NCT Number NCT04310826
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Ovarian Carcinoma
Enrollment 26 participants
Start Date 2019-04-23
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-21